Chris Ogden
Fortune : 461 070 $ au 31/05/2026
Fortune : 461 070 $ au 31/05/2026
Chris Ogden is currently Chief Financial Officer, Secretary & Senior VP at CytomX Therapeutics, Inc. since 2021.
Former roles include Chief Financial Officer-Diabetes Division at Eli Lilly & Co. and Chief Financial Officer & Treasurer at Lilly del Caribe, Inc. Education includes an undergraduate degree from Wabash College and an MBA from Harvard Business School.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/06/2026 | 128 075 ( 0,06 % ) | 461 070 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| CYTOMX THERAPEUTICS, INC. | Directeur Financier/CFO | 21/09/2022 |
| Sociétés | Poste | Fin |
|---|---|---|
Lilly del Caribe, Inc.
Lilly del Caribe, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Directeur Financier/CFO | - |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
Eli Lilly & Co.
Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
Wabash College
Wabash College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lilly del Caribe, Inc.
Lilly del Caribe, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Health Technology |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national